Compare NMT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMT | DTIL |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 97.7M |
| IPO Year | N/A | 2019 |
| Metric | NMT | DTIL |
|---|---|---|
| Price | $11.73 | $3.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 19.1K | ★ 213.6K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.05 | $3.72 |
| 52 Week High | $10.93 | $8.82 |
| Indicator | NMT | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 37.74 |
| Support Level | $11.60 | $3.83 |
| Resistance Level | $11.72 | $4.10 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 86.94 | 16.15 |
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.